I think MedReleaf was hit overly hard in the Canadian LP correction and expect it to recover about 1/2 its losses from the all-time high of C$31.25 to the low of C14.75 on 2/5. The company's financial report for FY18-Q3 showed an acceleration in sales to an all-time high after digesting changes in the Veterans Affairs program over the past several quarters. Pressuring the stock has been not only the recent public offering at 26.50 but also sales from original investors. The company has excess cash on its books now and is set to see sales explode from just its current footprint. Stay tuned, more to come!